BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Apollo Endosurgery, Inc. , Imago BioSciences, Inc. , Opiant Pharmaceuticals Inc. , Benefitfocus, Inc.

Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847. There is no cost or financial obligation to you.

Apollo Endosurgery, Inc. (Nasdaq - APEN)

Under the terms of the agreement, Apollo will be acquired by Boston Scientific Corporation ("Boston Scientific") (NYSE – BSX). Boston Scientific will acquire all outstanding shares of Apollo for $10.00 per share in cash for an approximate total enterprise value of $615 million. The investigation concerns whether the Apollo Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Boston Scientific is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/apollo-endosurgery-inc-nasdaq-apen/ .

Imago BioSciences, Inc. (Nasdaq - IMGO)

Under the terms of the agreement, Imago will be acquired by Merck (NYSE - MRK). Merck will acquire all outstanding shares of Imago for $36.00 per share in cash for an approximate total equity value of $1.35 billion. The investigation concerns whether the Imago Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Merck is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/imago-biosciences-inc-nasdaq-imgo/ .

Opiant Pharmaceuticals Inc. (Nasdaq - OPNT)

Under the terms of the agreement, Indivior PLC will acquire all of the outstanding shares of Opiant for upfront consideration of $20.00 per share in cash at closing, plus contingent value rights representing, if achieved, potential additional payments over a period of seven years of up to $8.00 per share. The investigation concerns whether the Opiant Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Indivior PLC is paying too little for the Company. For example, the deal consideration is less than the 52-week high of $37.71 for the Company's shares.

Additional information can be found at https://www.brodskysmith.com/cases/opiant-pharmaceuticals-inc-nasdaq-opnt/ .

Benefitfocus, Inc. (Nasdaq - BNFT)

Under the terms of the agreement, Benefitfocus will be acquired by Voya Financial, Inc. ("Voya") (NYSE - VOYA). Voya will pay $10.50 a share in cash for all outstanding shares of Benefitfocus in a deal valued at approximately $570 million. The investigation concerns whether the Benefitfocus Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Voya is paying too little for the Company. For example, the deal consideration is below the 52-week high of $13.06 for the Company's shares.

Additional information can be found at https://www.brodskysmith.com/cases/benefitfocus-inc-nasdaq-bnft/ .

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

MRK
The Conversation (0)
Raptor Resources

Eastern Metals Recommences ASX Trading – Aiming to Unlock High-Potential Copper Discoveries in New Brunswick, Canada

Eastern Metals Ltd (ASX: EMS) (Eastern Metals or the Company) (to be renamed Raptor Metals Ltd (ASX: RAP)) is pleased to advise it has recommenced trading on the Australian Securities Exchange (ASX) today following its acquisition of Raptor Resources Limited (Raptor Resources). HIGHLIGHTS... Keep Reading...
Merck Announces First-Quarter 2023 Financial Results

Merck Announces First-Quarter 2023 Financial Results

First Quarter 2023 Reflected Continued Strong Underlying Performance Across Key Growth Drivers, Particularly in Oncology and Vaccines Total Worldwide Sales Were $14.5 Billion, a Decrease of 9% From First Quarter 2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the Impact of... Keep Reading...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. , BELLUS Health Inc , Prometheus Biosciences, Inc. , Univar Solutions Inc.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. , BELLUS Health Inc , Prometheus Biosciences, Inc. , Univar Solutions Inc.

Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847. There is no cost or financial obligation to you.... Keep Reading...

BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson Health

Highlights: Grant awarded to Dr. Saveri Bhattacharya, Principal Investigator of the Phase I/IIa combination study of Bria-IMT™ with KEYTRUDA® (by Merck) in advanced breast cancer at Thomas Jefferson University. Merck to provide KEYTRUDA® for use in the combination study. The Investigator Grant... Keep Reading...

Merck Announces Q4 and Full-Year 2019 Financial Results

Merck (NYSE:MRK) reported quarterly worldwide sales at US$11.9 billion in Q4 in its financial results for the fourth quarter of 2019 and its full fiscal 2019 year. As quoted in the press release: As evidenced by our results and our 2020 guidance, Merck had an extraordinary year and is in a... Keep Reading...
Medical professional's hand under a digital interface with a glowing cross and circuit design.

Eli Lilly Brings AI to Drug Delivery in METiS TechBio Deal

METiS TechBio (HKEX:7666) could collect up to US$1.1 billion in milestone payments from Eli Lilly and Company (NYSE:LLY) under a new research pact to design lipid nanoparticles that carry medicines to specific tissues in the body.Lipid nanoparticles, or LNPs, carry therapeutic payloads to target... Keep Reading...
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. ("BriaPro"), today announced that four... Keep Reading...
Two people wearing lab coats shake hands in business agreement.

Telix Acquires Germany's ITM in US$1.65 Billion Deal

Melbourne-based Telix Pharmaceuticals (ASX:TLX) has agreed to acquire Germany’s ITM Isotope Technologies to secure commercial-scale radioisotope manufacturing and expand into neuroendocrine tumor treatments.The deal brings ITM’s global radioisotope production and distribution network spanning... Keep Reading...
Data Safety Monitoring Board  Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study

Data Safety Monitoring Board Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study

Independent DSMB reports no safety concerns to date and recommends continuing BriaCell's pivotal Phase 3 study of Bria-IMTâ„¢ plus an immune checkpoint inhibitorSeventh consecutive positive DSMB recommendation reinforces the favorable safety and tolerability of BriaCell's novel immunotherapy... Keep Reading...
BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)BriaCell Phase 3 trial featured in Nature Medicine as "Eleven clinical trials that will shape medicine in 2026" briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage... Keep Reading...

Interactive Chart

Latest Press Releases

Related News